Company Overview
Curis, Inc. operates within the healthcare sector, specifically focusing on the biotechnology industry where it engages in the discovery and development of drug candidates intended for the treatment of human cancers in the United States. The company's clinical stage portfolio features Emavusertib, an oral small-molecule IRAK4 kinase inhibitor that is currently undergoing evaluation in a Phase 1/2 open-label, single-arm trial. As a public entity, Curis, Inc. maintains a market capitalization of $22.21M, which reflects a relatively small scale compared to large-cap pharmaceutical peers, while its annual revenue over the trailing twelve months stands at $9.44M. The absence of reported employee data suggests the company operates with a lean organizational structure typical of early-stage biotechnology firms. These financial figures indicate that the company is in a capital-intensive development phase where revenue generation is limited, and the market cap size suggests high sensitivity to clinical trial outcomes and regulatory milestones rather than established commercial cash flows.
Financial Health
Over the trailing twelve months, the company reported a revenue of $9.44M, a net income of $-7,582,000, and an EBITDA of $-32,733,000. The significant gap between the positive revenue of $9.44M and the substantial net loss of $-7,582,000 reveals a cost structure dominated by research and development expenses, administrative costs, and operational overhead that far exceeds current sales. The free cash flow stands at $-10,457,375, indicating that the company is burning cash at a rate of approximately $10.5M annually, which implies limited financial flexibility for funding operations without external financing or asset liquidation. The gross margin is reported at -199.7%, which indicates that the cost of goods sold exceeds total revenue, a common characteristic in biotechnology where manufacturing costs for clinical trials often outweigh direct sales. The operating margin of -665.2% and the profit margin of -80.3% further illustrate the deep losses incurred at the operational level and overall profitability, respectively. In terms of liquidity, the company holds $5.06M in cash against $1.62M in debt, resulting in a debt-to-equity ratio of 29.62. Despite the low absolute debt level, the debt-to-equity ratio suggests a leveraged position relative to equity, though the absolute dollar amount of debt is manageable against available cash reserves. The current ratio is 0.49, which indicates that the company's current assets are less than its current liabilities, signaling potential short-term liquidity constraints that require careful management of cash burn. Return on Equity is not applicable, while the Return on Assets is -67.2%, revealing that the company is generating negative returns on its asset base, which is typical for biotechnology firms in the pre-commercialization stage where assets are heavily tied up in intellectual property and development programs.
Valuation Assessment
The trailing twelve-month P/E ratio is not applicable due to the lack of positive earnings, whereas the forward P/E is -0.58. The existence of a negative forward P/E alongside an unavailable trailing P/E implies that the market is pricing in continued losses or expects earnings to remain negative in the near term, making traditional earnings-based valuation metrics invalid for this stage of the company. The price-to-book ratio stands at 1.32, indicating that the market values the company at 1.32 times its book value, which suggests a modest premium over the net asset value despite the company's current unprofitability. The price-to-sales ratio is 2.35, and the EV/EBITDA is -0.57; these alternative valuation metrics suggest that investors are willing to pay a significant multiple of sales for a company that generates no earnings, placing the valuation entirely on the potential of future drug candidates. The 52-week high for the stock is $3.13 and the 52-week low is $0.52. Without a specific current price provided in the facts, the trading range indicates a stock that has experienced significant volatility, moving from $0.52 to $3.13 over the past year. The beta value is 2.98, which means the stock's price volatility is nearly three times that of the broader market, indicating extreme sensitivity to market movements and specific biotechnology sector sentiment.
Growth & Income
The revenue growth year-over-year is -66.0%, while the earnings growth year-over-year is not applicable. The negative revenue growth of -66.0% combined with the absence of positive earnings growth indicates that the company is shrinking in top-line sales and has not yet achieved profitability, implying that the business model relies on future commercialization rather than current expansion. Since the company has a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute dividends to shareholders. This lack of dividend distribution confirms that the company reinvests all available resources, including its $5.06M cash balance, into research and development activities rather than paying returns to investors. The overall growth and income profile is characterized by negative revenue expansion and zero dividend income, reflecting the typical trajectory of a biotechnology firm in the clinical development phase where capital preservation and product advancement take precedence over shareholder distributions.